INTERFERONS IN ONCOLOGY

SUMMARY The interferons are natural glycoproteins secreted in response to various stimuli, including viral infection. They have antiviral, antiproliferative and immunomodulatory effects on different target cell populations. Since recombinant human interferons have become available, they have been tested in a wide range of malignancies. They are well established in the treatment of hairy cell leukaemia, chronic myelogenous leukaemia and multiple myeloma. Although they have documented activity against lymphoma, melanoma, renal cell cancer and carcinoid tumours, their role in the treatment of these tumours is less clear. In the common solid tumours, such as lung cancer and colorectal cancer, the use of interferons remains experimental. Here we will summarise their practice applications in oncology, using randomised studies where available to establish their place in multi‐modality treatment. We will not discuss their use as antiviral or immunomodulating agents in viral and autoimmune diseases, multiple sclerosis or after organ transplantation.

[1]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[2]  S. Fosså,et al.  Interferon-alpha and survival in renal cell cancer. , 1995, British journal of urology.

[3]  S. Richards,et al.  UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.

[4]  W. Scheithauer,et al.  Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. , 1995, European journal of cancer.

[5]  M. Kriegmair,et al.  Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. , 1995, Urology.

[6]  H. Senn,et al.  Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Grever,et al.  Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Cortelezzi,et al.  Interferon alfa‐2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study , 1995, British journal of haematology.

[9]  C. Falkson Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma , 1995, Medical oncology.

[10]  F. de Marinis,et al.  Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. , 1995, British Journal of Cancer.

[11]  S. Rosenberg,et al.  Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.

[12]  J. Jett,et al.  Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Queirolo,et al.  Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Eggermont,et al.  Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. , 1994, Melanoma research.

[15]  G. Flandrin,et al.  Hairy cell leukemia. An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. , 1994, Leukemia & lymphoma.

[16]  B. Coiffier,et al.  Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.

[17]  G. Scagliotti,et al.  Combination of chemotherapy and recombinant alpha‐interferon in advanced non‐small cell lung cancer: Multicentric randomized FONICAP trial report , 1993, Cancer.

[18]  P. Hersey,et al.  Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. , 1993, Melanoma research.

[19]  G. Gahrton,et al.  Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden , 1993 .

[20]  W. Velasquez,et al.  CHOP-Bleo plus interferon for stage IV low-grade lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  S. McDonald,et al.  Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. , 1993, International journal of radiation oncology, biology, physics.

[22]  R. Dorr Interferon-alpha in malignant and viral diseases. A review. , 1993, Drugs.

[23]  M. Oken,et al.  Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.

[24]  D. Grandér,et al.  Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  K. Cantell,et al.  Natural interferon alfa as maintenance therapy for small cell lung cancer. , 1992, European journal of cancer.

[26]  P. Volberding,et al.  Interferon-α2a in the Treatment of Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma , 1991 .

[27]  K. Öberg The Role of Interferons in Neuroendocrine Tumours and Aspects of Mechanisms of Action , 1991 .

[28]  M. Ratain,et al.  Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B. , 1991, Leukemia & lymphoma.

[29]  S. Wadler,et al.  Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.

[31]  J. Lindenmann,et al.  Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.